MRKClinical Trials•businesswire•August 30, 2025 at 06:45 AM

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

Sentiment:Negative (25)

Summary

(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 30, 2025 by businesswire